Stroke and Bleeding Risk Associated With Antithrombotic Therapy for Patients With Nonvalvular Atrial Fibrillation in Clinical Practice

JaeJin An, BPharm, PhD; Fang Niu, MS; Daniel T. Lang, MD; Kristin P. Jazdzewski, PharmD; Paul T. Le, PharmD; Nazia Rashid, PharmD, MS; Brian Meissner, PharmD, PhD; Robert Mendes, MD; Diana G. Dills, MD; Gustavus Aranda, Jr., PharmD, MS; Amanda Bruno, PhD, MPH

Background—The quality of antithrombotic therapy for patients with nonvalvular atrial fibrillation during routine medical care is often suboptimal. Evidence linking stroke and bleeding risk with antithrombotic treatment is limited. The purpose of this study was to evaluate the associations between antithrombotic treatment episodes and outcomes.

Methods and Results—A retrospective longitudinal observational cohort study was conducted using patients newly diagnosed with nonvalvular atrial fibrillation with 1 or more stroke risk factors (CHADS2 ≥1) in Kaiser Permanente Southern California between January 1, 2006 and December 31, 2011. A total of 1782 stroke and systemic embolism (SE) and 3528 major bleed events were identified from 23 297 patients during the 60 021 person-years of follow-up. The lowest stroke/SE rates and major bleed rates were observed in warfarin time in therapeutic range (TTR) ≥55% episodes (stroke/SE: 0.87 [0.71 to 1.04]; major bleed: 4.91 [4.53 to 5.28] per 100 person-years), which was similar to the bleed rate in aspirin episodes (4.95 [4.58 to 5.32] per 100 person-years). The warfarin TTR ≥55% episodes were associated with a 77% lower risk of stroke/SE (relative risk=0.23 [0.18 to 0.28]) compared to never on therapy; and the warfarin TTR <55% and on-aspirin episodes were associated with a 20% lower and with a 26% lower risk of stroke/SE compared to never on therapy, respectively. The warfarin TTR <55% episodes were associated with nearly double the risk of a major bleed compared to never on therapy (relative risk=1.93 [1.74 to 2.14]).

Conclusions—Continuation of antithrombotic therapy as well as maintaining an adequate level of TTR is beneficial to prevent strokes while minimizing bleeding events. (J Am Heart Assoc. 2015;4:e001921 doi: 10.1161/JAHA.115.001921)

Key Words: antithrombotic • atrial fibrillation • bleeding • outcomes research • stroke

Nonvalvular atrial fibrillation (NVAF) is the most common cardiac arrhythmia, affecting ≈5.2 million people in the United States.1 The rate of ischemic strokes among NVAF patients averages 5% per year, 2 to 7 times higher than people without NVAF.2 Clinical guidelines recommend oral anticoagulants for NVAF patients to prevent thromboembolism and suggest maintaining the target international normalized ratio (INR) for patients treated with warfarin.3,4

The quality of antithrombotic therapy (either anticoagulant or antiplatelet) during routine medical care is often suboptimal. Previous studies showed that 30% to 40% of those at high risk for stroke fail to receive recommended anticoagulant therapy5–8 and even after they start on warfarin therapy, ≈30% of patients discontinued their warfarin within 1 year.9,10 Also, the quality of warfarin therapy is often suboptimal; the average of time in therapeutic range (TTR) of INR values ranged from 51% to 63% based on the management setting in the United States.11

Understanding outcomes of antithrombotic treatment patterns in a real-world setting is critical; however, the evidence is still unclear. Over-the-counter aspirin use is usually missing in an observational data set, and the outcomes associated with TTR levels in clinical practice have not been extensively studied. Several analyses of randomized controlled trials12–16 and some observational studies17,18 have examined the relationship between TTR and clinical events. In general, these studies demonstrated the decreased stroke rates in higher TTR, whereas the relationship between the higher TTR and bleeding risk has been more variable.19

The purpose of this study was to evaluate the associations between different antithrombotic treatments—warfarin TTR ≥55%, warfarin TTR <55%, off warfarin, on aspirin, off aspirin, and never on antithrombotic therapy—and their clinical

Received March 18, 2015; accepted June 21, 2015.

© 2015 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
outcomes (strokes, systemic embolism [SE], and major bleeding) for moderate stroke-risk patients (congestive heart failure, hypertension, age ≥75, diabetes, stroke/transient ischemic attack, CHADS₂ ≥1) with NVAF in clinical practice.

Methods
Study Design
A retrospective longitudinal observational cohort study was conducted considering multiple antithrombotic treatments for each individual. Patients may have had multiple treatment and nontreatment times during the entire follow-up period (eg, stop therapy, switch therapy, and restart therapy). The dynamics of treatment patterns and outcomes associated with them were captured in a longitudinal analysis.

Study Setting
Study population was identified from Kaiser Permanente Southern California (KPSC). KPSC is a nonprofit, integrated healthcare delivery organization with a membership of over 3.6 million people in Southern California. KPSC provides integrated, comprehensive medical services through its own facilities, which include 14 hospitals, >200 outpatient facilities, and a centralized laboratory. All aspects of care and interaction with the healthcare delivery system are captured in a continuously updated electronic medical record (EMR) system. Over 95% of the patients receiving warfarin treatment in KPSC are participants of anticoagulation clinics led by pharmacists. Each encounter (mostly telephone counseling) at an anticoagulation clinic is stored in the EMR system.

Study Cohort
Patients newly diagnosed with atrial fibrillation (≥ 2 serial International Classification of Diseases, Ninth Revision Clinical Modification [ICD-9-CM] of 427.31 ≥ 30 days apart) in outpatient visit or hospital records were identified between January 1, 2006 and December 31, 2011. The first diagnosis date was defined as the index date and patients were followed until the first outcomes of interest, end of enrollment, death, or December 31, 2012, whichever occurred first. Individuals who had a history of atrial fibrillation diagnosis, ablation, cardioversion, warfarin prescription, or an anticoagulation clinic visit during 12 months prior to the index date were excluded to ensure that only newly diagnosed NVAF patients were captured. Patients <18 years old at index, without continuous health-plan membership or drug benefit during the 12 months prior to the index date (gaps of ≤ 30 days were treated as continuous membership), evidence of pregnancy at any point during the entire follow-up period, and individuals who had valvular diseases, valvular repair, or replacement 12 months prior to the index date were also excluded. In the final study cohort, we excluded patients on novel oral anticoagulation agents (dabigatran and rivaroxaban: N=101) due to small sample size, and patients who only had 1 warfarin prescription but were not followed by an anticoagulation clinic (N=133), since it would be difficult to confirm these patients were taking warfarin due to lack of monitoring. The analyses were conducted for patients with at least 1 or more major risk factors for stroke (CHADS₂ ≥1). The current study was reviewed and approved by the KPSC Institutional Review Board. Informed consent was waived due to the retrospective observational nature of this study.

Antithrombotic Therapy Definitions
Warfarin treatment (TTR ≥ 55%, TTR < 55%, off warfarin episodes)
We defined warfarin treatment episodes using prescriptions, INR lab measurements, and anticoagulation clinic data. The start date of a warfarin episode was defined as the first warfarin prescription date, and the end date of the episode was defined as the earliest date with one for the following: (1) date of discharge from the anticoagulation clinic; or (2) the most recent covered date (last refill date plus days’ supply) plus additional 80 days of grace period to incorporate interpersonal variability of warfarin dosage use; or (3) INR measurement date plus 80 days of grace period (regular INR measurement intervals at KPSC [8 weeks] and around 4 weeks of additional period) from the date of discharge. Previous literature applied 30 days of grace period at the end of a prescription because patients may be instructed to take half-doses of warfarin. Applying a similar concept, we determined 80 days of grace period since this is a mean warfarin days’ supply at KPSC.

TTR was calculated using the linear interpolation method by Rosendaal et al expressed as a percentage of observation time, which in our study we defined as each warfarin treatment episode. We considered the INR range of 2 to 3 as therapeutic. INR tests performed during hospitalization or INR gaps > 80 days were not interpolated. Based on TTR, we stratified patients into 2 different groups (warfarin TTR ≥ 55%, warfarin TTR < 55%). There is no consensus in terms of appropriate TTR cutoff. The 55% threshold was selected a priori since this level is the lower bound of reported means from previous clinical trials and large observational studies. The 55% threshold may be understood as the initial cutoff for poor control. Stratified analyses were conducted to investigate the outcomes at the different TTR levels based on the distribution of the data. No treatment time after warfarin use was considered “off warfarin” period.
Aspirin-only treatment (on aspirin, off aspirin episodes)

Low-dose aspirin (75 to 325 mg) use in the EMR, chart notes, and prescription data were searched for the entire nonwarfarin time. We built a natural language processing algorithm\textsuperscript{24–26} to search for low-dose aspirin use information, and \( \geq 1 \) evidence of aspirin use was considered as being on aspirin. Chart notes (5339) from 100 patients’ records were randomly selected and manually reviewed to validate the algorithm. The algorithm achieved 95.5% sensitivity and 98.9% specificity. The positive predictive value was 93.0% with negative predictive value of 99.3%. We applied \( \pm 180 \) days criteria for the first and the last evidence of aspirin use and assumed patients were on aspirin during this period. The nontreatment time after aspirin use was considered as “off aspirin” period.

No therapy (“never on therapy” episode)

Some patients were never on warfarin or aspirin therapy. Thus, the entire follow-up time for this patient group was considered as “never on therapy” episode. There was another group of patients who started warfarin or aspirin therapy after their index date. The time between the index date to the first use of warfarin or aspirin was considered as a “never on therapy” period since they were not on a therapy until their first medication.

Outcomes Definition

The outcomes of interest were stroke and/or SE (stroke/SE) and major bleed. Primary hospital discharge diagnoses of stroke (ICD-9-CM of 430, 431, 433.xx, 434.xx, 436.xx)

Table 1. Definition of Outcomes

| ICD-9-CM or CPT Codes | Definition |
|-----------------------|------------|
| Stroke/systemic embolism | All stroke or systemic embolism |
| Stroke | Primary hospital discharge record 430, 431, 433.xx, 434.xx, 436.xx |
| Systemic embolism | Primary hospital discharge record 444.0, 444.1, 444.2x, 444.8x, 444.9, 557.x, 593.81 |
| Bleeding events | |
| Major bleeding | A bleeding event will be defined as major if it was an intracranial bleed or any other bleed that was associated with the following: inpatient care, blood transfusion of 2 or more units of whole blood or red blood cells, decreased hemoglobin or hematocrit of 2 g/dL or more, physician-guided medical or surgical treatment, or death* |
| Intracranial hemorrhage | Primary or secondary hospital discharge record 432.x |
| Exclude intracranial hemorrhage associated with a concomitant discharge diagnosis of major trauma (ICD-9-CM codes 852.1, 852.3, 852.5, and 853.1) |
| Gastrointestinal bleeding | Primary hospital discharge record 530.21, 530.7, 530.82, 531.0x, 531.2x, 531.4x, 531.6x, 532.0x, 532.2x, 532.31, 532.4x, 532.6x, 534.0x, 534.2x, 534.4x, 534.6x, 535.x1, 537.83, 537.84, 537.89, 562.02, 562.03, 562.12, 562.13, 568.81, 569.3, 569.69, 569.85, 577.8, 578.x, 580.9, 596.7, 596.8, 599.7x |
| Other bleeding (intraspinal, intraocular, pericardial, intra-articular, intramuscular, etc) | Primary hospital discharge record 255.41, 423.0, 455.2, 455.5, 455.8, 456.0, 456.2, 456.8, 459.0, 719.1x, 784.7, 784.8, 785.59, 786.3, 853.0x |
| Others | To define major bleeding |
| Physician-guided medical or surgical treatment* | From primary or secondary hospital discharge record |
| CPT codes: 10140, 10160, 11740, 21501, 21502, 23030, 23930, 25028, 26990, 27301, 27603, 30000, 30020, 30901, 30903, 30905, 30906, 31238, 32110, 32654, 32658, 33020, 40800, 40801, 40100, 41005, 41006, 41007, 41008, 41009, 41015, 41016, 41017, 41018, 41800, 42960, 42961, 42962, 42970, 42971, 42972, 43227, 43255, 43460, 43501, 44366, 44378, 44391, 45317, 45334, 45352, 45362, 45614, 47350, 47360, 47361, 47362, 52606, 54700, 57023, 57180, 61154, 61156, 61158, 61312, 61313, 61314, 61322, 61323, 65930, 69000, 69005, 91100 |
| ICD-9-CM procedure codes: 44.43, 44.44, 44.49 |

CPT indicates Current Procedural Terminology; ICD-9-CM, International Classification of Diseases, Ninth Revision Clinical Modification.

*Death information may not be complete since there is a 1-year delay in receiving death information from California State death records, and federal sources.
and/or SE (444.0, 444.1, 444.2x, 444.8x, 444.9, 557.x, 593.81) was defined as an outcome. Major bleed was defined as an intracranial bleed or any other bleed (gastrointestinal, intraspinal, intraocular, pericardial, intrarticular, intramuscular bleed) that was associated with an inpatient care visit; blood transfusion of 2 or more units of whole blood or red blood cells; decreased hemoglobin 2 g/dL or more; physician-guided medical or surgical treatment; or death (Table 1). Decreased hemoglobin was identified by searching 7 days before and 7 days after the bleed diagnosis codes and determining nadir hemoglobin level. The highest hemoglobin level before the nadir level was considered as a baseline value and was compared with the nadir level. A decrease in 2 g/dL or more was considered a major hemorrhage according to the definition published by the International Society on Thrombosis and Hemostasis.27

Statistical Analyses

Patient-level baseline characteristics were investigated and descriptive statistics were reported to examine differences among each treatment option (warfarin use, aspirin only, and no therapy). The crude rate of stroke/SE and major bleeding (number of events per 100 person-years [PY]) were evaluated for each treatment episode. Longitudinal multivariable analyses using generalized estimating equations (logit link, Poisson distribution) were conducted considering interindividual correlations. Patient demographics (age, gender, race/ethnicity), body mass index, baseline comorbidities (peripheral vascular disease, cirrhosis, cardiac myopathy, dementia), history of bleed, myocardial infarction, or fall, and baseline medication use (periprocedural anticoagulation, antiarrhythmic medications, clopidogrel, ticlopidine, prasugrel, ticagrelor, heart rate control medications, statin, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) were considered as covariates. P-value <0.2 in the univariate analysis, and other clinically relevant covariates were included in the multivariable regression model. The final multivariable model was created by applying a backward model selection procedure that retained those covariates with P<0.05. Other clinically relevant covariates that were not significant were forced into the final model as needed. We used key risk factors such as age, congestive heart failure, hypertension, diabetes, stroke/transient ischemic attack, and major bleed as time-varying covariates. Relative risks (RR) with 95% CI were reported from the multivariable analyses. Subgroup analyses were conducted based on the baseline CHADS₂ scores (1, 2, ≥3). The outcomes based on TTR distribution were investigated.

Results

A total of 23,297 patients with CHADS₂ ≥1 were included in the study. A cohort diagram is shown in Figure 1. Data were censored at the first occurrence of each outcome of interest; a total of 60,021 PY for stroke/SE outcomes, and 56,760 PY for major bleed outcomes were identified in this study. Among the population, 47.5% had at least 1 warfarin prescription, 29.0% had evidence of aspirin use only, and 23.5% did not receive any antithrombotic therapy. Mean (SD) age of the population was 74.9 (11.1) years, and 47.7% were female. The median TTR for the warfarin group was 59%. Baseline characteristics are shown in Table 2. Baseline differences were found among 3 different treatment groups (warfarin, aspirin only, and no therapy). Mean (SD) age of the aspirin-only group was higher compared to warfarin users (77.6 [10.8] for aspirin versus 73.1 [10.3] for warfarin) and a higher percentage of patients age ≥85 was found in the aspirin-only group. Warfarin users had higher rates of comorbidities: hypertension, diabetes, and stroke/transient ischemic attack compared to the aspirin-only group, whereas the aspirin-only and no-therapy groups had higher rates of
congestive heart failure, myocardial infarction, and bleeding. A higher percentage of patients with CHADS2 ≥2 was found in the aspirin group compared to the warfarin or no-therapy groups.

A total of 1782 stroke/SE events occurred during the follow-up period. The lowest stroke/SE rates (95% CI) were observed in the warfarin TTR ≥55% episodes (0.87 [0.71 to 1.04] per 100 PY) (Table 3). The stroke/SE event rates from

| Variables                              | Warfarin (N=11 079) | Aspirin Only (N=6746) | No Therapy (N=5472) | Total (N=23 297) |
|----------------------------------------|---------------------|----------------------|---------------------|------------------|
| Age, mean (SD)                         | 73.1 (10.3)         | 77.6 (10.8)          | 75.0 (12.3)         | 74.9 (11.1)      |
| Age category, y, N (%)                 |                     |                      |                     |                  |
| Age <65                                 | 2172 (19.6)         | 877 (13)             | 1080 (19.7)         | 4129 (17.7)      |
| Age 65 to 74                            | 3219 (29.1)         | 1322 (19.6)          | 1202 (22)           | 5743 (24.7)      |
| Age 75 to 84                            | 4421 (39.9)         | 2600 (38.5)          | 1893 (34.6)         | 8914 (38.3)      |
| Age ≥85                                 | 1267 (11.4)         | 1947 (28.9)          | 1297 (23.7)         | 4511 (19.4)      |
| Gender, N (%)                           |                     |                      |                     |                  |
| Female                                  | 5161 (46.6)         | 3291 (48.8)          | 2665 (48.7)         | 11117 (47.7)     |
| Charlson Comorbidity Score, mean (SD)  | 2.4 (3.04)          | 2.6 (3.30)           | 2.5 (3.37)          | 2.5 (3.20)       |
| Charlson Comorbidity Score category, N (%) |                 |                      |                     |                  |
| 0                                      | 4769 (43)           | 3049 (45.2)          | 2559 (46.8)         | 10377 (44.5)     |
| 1 to 3                                 | 3281 (29.6)         | 1699 (25.2)          | 1356 (24.8)         | 6336 (27.2)      |
| 4 or more                              | 3029 (27.3)         | 1998 (29.6)          | 1557 (28.5)         | 6584 (28.3)      |
| Comorbid conditions or event, N (%)    |                     |                      |                     |                  |
| Congestive heart failure                | 1953 (17.6)         | 1321 (19.6)          | 1011 (18.5)         | 4285 (18.4)      |
| Hypertension                            | 9688 (87.4)         | 5615 (83.2)          | 4548 (83.1)         | 19851 (85.2)     |
| Diabetes mellitus                      | 3608 (32.6)         | 2016 (29.9)          | 1583 (28.9)         | 7207 (30.9)      |
| Stroke/transient ischemic attack        | 407 (3.7)           | 160 (2.4)            | 202 (3.7)           | 769 (3.3)        |
| Peripheral vascular disease            | 772 (7)             | 593 (8.8)            | 408 (7.5)           | 1773 (7.6)       |
| Myocardial infarction                   | 368 (3.3)           | 283 (4.2)            | 172 (3.1)           | 823 (3.5)        |
| Cardiomyopathy                          | 708 (6.4)           | 419 (6.2)            | 297 (5.4)           | 1424 (6.1)       |
| Liver cirrhosis                         | 41 (0.4)            | 49 (0.7)             | 84 (1.5)            | 174 (0.7)        |
| Dementia                                | 69 (0.6)            | 149 (2.2)            | 128 (2.3)           | 346 (1.5)        |
| Bleeding                                | 742 (6.7)           | 602 (8.9)            | 531 (9.7)           | 1875 (8)         |
| Fall                                    | 100 (0.9)           | 151 (2.2)            | 93 (1.7)            | 344 (1.5)        |
| CHADS2 scores, N (%)                    |                     |                      |                     |                  |
| 1                                      | 3773 (34.1)         | 2095 (31.1)          | 2031 (37.1)         | 7899 (33.9)      |
| 2                                      | 4667 (42.1)         | 2764 (41)            | 2069 (37.8)         | 9500 (40.8)      |
| 3 or more                              | 2639 (23.8)         | 1887 (28)            | 1372 (25.1)         | 5989 (25.3)      |
| Other pharmacologic treatment, N (%)   |                     |                      |                     |                  |
| Heart rate control                      | 7520 (67.9)         | 4504 (66.8)          | 3495 (63.9)         | 15519 (66.6)     |
| Antiarrhythmic medications             | 294 (2.7)           | 322 (4.8)            | 222 (4.1)           | 838 (3.6)        |
| Secondary prevention of cardiovascular disease | 8738 (78.9)      | 5076 (75.2)          | 3864 (70.6)         | 17678 (75.9)     |
| Other antiplatelet agents*             | 805 (7.3)           | 525 (7.8)            | 459 (8.4)           | 1789 (7.7)       |
| Periprocedural anticoagulation          | 1037 (9.4)          | 715 (10.6)           | 527 (9.6)           | 2279 (9.8)       |
| Median time in therapeutic range (INR 2 to 3) (%) | 59%     | —                   | —                   | —                |

INR indicates international normalized ratio.
*Clopidogrel, ticlopidine, prasugrel, ticagrelor use.
Table 3. Crude Rate of Stroke/Systemic Embolism and Major Bleed Events

|                          | Warfarin TTR ≥55% | Warfarin TTR <55% | Off Warfarin | On Aspirin | Off Aspirin | Never on Therapy | Total          |
|--------------------------|-------------------|-------------------|--------------|------------|-------------|------------------|----------------|
| **Stroke/SE**            |                   |                   |              |            |             |                  |                |
| Number of episode        | 5960 (12 928)     | 5292 (5603)       | 10 092 (3679)| 11 794 (15 029)| 5219 (5329) | 15 603 (17 453) | 53 960 (60 021) |
| (total person-years)     |                   |                   |              |            |             |                  |                |
| All patients             | 0.87 (0.71 to 1.04)| 3.23 (2.76 to 3.70)| 4.38 (3.70 to 5.05)| 3.11 (2.83 to 3.39)| 3.81 (3.29 to 4.33)| 3.76 (3.48 to 4.05)| 2.97 (2.83 to 3.11) |
| (N=23 297)               |                   |                   |              |            |             |                  |                |
| Ischemic stroke          | 0.64 (0.50 to 0.78)| 2.52 (2.10 to 2.93)| 2.80 (2.26 to 3.34)| 2.64 (2.38 to 2.90)| 3.17 (2.69 to 3.65)| 3.04 (2.78 to 3.30)| 2.37 (2.25 to 2.50) |
| Hemorrhagic stroke       | 0.09 (0.09 to 0.14)| 0.29 (0.15 to 0.43)| 1.14 (0.80 to 1.49)| 0.13 (0.07 to 0.18)| 0.30 (0.15 to 0.45)| 0.29 (0.21 to 0.37)| 0.26 (0.22 to 0.30) |
| SE                       | 0.15 (0.08 to 0.21)| 0.43 (0.26 to 0.61)| 0.43 (0.22 to 0.65)| 0.34 (0.25 to 0.43)| 0.34 (0.18 to 0.49)| 0.43 (0.33 to 0.53)| 0.34 (0.29 to 0.38) |
| CHADS2=1 (N=7899)        | 0.68 (1.45 to 0.92)| 1.78 (1.16 to 2.40)| 1.97 (1.27 to 2.68)| 2.06 (1.65 to 2.47)| 2.09 (1.44 to 2.75)| 1.73 (4.13 to 2.03)| 1.62 (1.46 to 1.79) |
| CHADS2=2 (N=9500)        | 1.05 (0.78 to 1.32)| 3.61 (2.64 to 4.37)| 5.53 (4.28 to 6.78)| 3.29 (2.85 to 3.73)| 4.05 (3.22 to 4.88)| 3.84 (3.37 to 4.31)| 3.15 (2.93 to 3.37) |
| CHADS2=3 or higher       | 0.84 (0.48 to 1.20)| 4.42 (3.34 to 5.50)| 6.98 (5.15 to 8.81)| 4.06 (3.42 to 4.69)| 5.99 (4.62 to 7.37)| 7.93 (6.99 to 8.86)| 4.85 (4.48 to 5.23) |
| (N=5898)                 |                   |                   |              |            |             |                  |                |
| **Major bleed**          |                   |                   |              |            |             |                  |                |
| Number of episode        | 6096 (13 226)     | 5354 (5687)       | 8836 (2667) | 10 894 (14 004)| 4423 (4514) | 15 162 (16 662)| 50 765 (56 760) |
| (total person-years)     |                   |                   |              |            |             |                  |                |
| All patients             | 4.91 (4.53 to 5.28)| 12.33 (11.41 to 13.24)| 9.56 (8.39 to 10.73)| 4.95 (4.58 to 5.32)| 5.23 (4.56 to 5.89)| 5.97 (5.59 to 6.34)| 6.22 (6.01 to 6.42) |
| (N=23 297)               |                   |                   |              |            |             |                  |                |
| ICH                      | 0.21 (0.13 to 0.29)| 0.44 (0.27 to 0.61)| 1.65 (1.16 to 2.14)| 0.16 (0.10 to 0.23)| 0.31 (0.15 to 0.47)| 0.35 (0.26 to 0.44)| 0.34 (0.29 to 0.39) |
| Gl bleed                 | 2.98 (2.68 to 3.27)| 8.42 (7.67 to 9.18)| 6.30 (5.35 to 7.25)| 3.73 (3.41 to 4.05)| 3.74 (3.18 to 4.31)| 4.39 (4.07 to 4.71)| 4.34 (4.17 to 4.51) |
| Other bleed              | 1.72 (1.49 to 1.94)| 3.46 (2.98 to 3.95)| 1.61 (1.13 to 2.09)| 1.05 (0.88 to 1.22)| 1.17 (0.86 to 1.49)| 1.22 (1.06 to 1.39)| 1.53 (1.43 to 1.64) |
| CHADS2=1 (N=7899)        | 3.80 (3.25 to 4.34)| 10.43 (8.94 to 11.92)| 5.47 (4.10 to 6.85)| 2.93 (2.39 to 3.47)| 2.16 (1.33 to 2.98)| 4.26 (3.78 to 4.74)| 4.39 (4.10 to 4.68) |
| CHADS2=2 (N=9500)        | 5.07 (4.49 to 5.66)| 12.38 (10.96 to 13.79)| 10.76 (8.72 to 12.80)| 4.85 (4.28 to 5.41)| 5.31 (4.23 to 6.38)| 6.43 (5.80 to 7.06)| 6.41 (6.08 to 6.74) |
| CHADS2=3 or higher       | 6.61 (5.62 to 7.59)| 14.52 (12.60 to 16.44)| 15.59 (12.31 to 18.86)| 6.89 (6.10 to 7.67)| 7.52 (6.16 to 8.88)| 8.75 (7.74 to 9.75)| 8.53 (8.04 to 9.01) |
| (N=5898)                 |                   |                   |              |            |             |                  |                |

Gl indicates gastrointestinal; ICH, intracranial hemorrhage; SE, systemic embolism; TTR, time in therapeutic range.

the warfarin TTR <55% episodes were similar (3.23 [2.76 to 3.70] per 100 PY) compared to the event rates during episodes of aspirin use (3.11 [2.83 to 3.39] per 100 PY). Higher occurrences of stroke/SE were observed during periods of no treatment (off warfarin, off aspirin, and never on therapy). The highest stroke/SE rates were found during
the off-warfarin therapy episodes (4.38 [3.70 to 5.05] per 100 PY). The majority of the total stroke/SE events were from ischemic stroke (79.9%) and 8.7% were from hemorrhagic stroke.

A total of 3528 major bleed events occurred during the follow-up period. The lowest major bleed rates (95% CI) were also found during warfarin TTR $\geq 55\%$ episodes (4.91 [4.53 to 5.32] per 100 PY), and these were similar to the rates observed during episodes of aspirin use (4.95 [4.58 to 5.32] per 100 PY) (Table 3). Bleeding rates were the highest in warfarin TTR $<55\%$ episodes (12.33 [11.41 to 13.24] per 100 PY), followed by off-warfarin episodes (9.56 [8.39 to 10.73] per 100 PY). A large proportion (69.8%) of major bleeds was gastrointestinal bleeds and 5.5% were from intracranial hemorrhages.

When controlling for other factors and individual correlations due to an individual patient having multiple episodes, warfarin TTR $\geq 55\%$ episodes were associated with a 77% lower risk of stroke/SE (adjusted RR [95% CI] = 0.23 [0.18 to 0.28]) compared to never on therapy episodes, whereas warfarin TTR $<55\%$ and on-aspirin episodes were associated with a 20% lower risk and with a 26% lower risk of stroke/SE compared to never on therapy episodes (Table 4).

### Table 4. Factors Associated With Stroke/SE

| Variables                                           | Thromboembolic Events | 95% CI       | P Value |
|-----------------------------------------------------|-----------------------|--------------|---------|
|                                                     | Relative Risk         |              |         |
| **Time-varying antithrombotic treatment**           |                       |              |         |
| Warfarin TTR $\geq 55\%$ (vs never on therapy)     | 0.23*                 | 0.18         | 0.28    |
| Warfarin TTR $<55\%$ (vs never on therapy)         | 0.80*                 | 0.67         | 0.95    |
| Off warfarin (vs never on therapy)                  | 1.22*                 | 1.01         | 1.48    |
| On aspirin (vs never on therapy)                    | 0.74*                 | 0.65         | 0.83    |
| Off aspirin (vs never on therapy)                   | 0.96                  | 0.82         | 1.13    |
| **Time-invariant factors**                          |                       |              |         |
| Female (vs male)                                    | 1.34*                 | 1.22         | 1.48    |
| Black (vs white)                                    | 1.51*                 | 1.29         | 1.76    |
| Hispanic (vs white)                                 | 1.16*                 | 1.00         | 1.34    |
| Asian and others (vs white)                         | 1.05                  | 0.86         | 1.29    |
| Baseline peripheral vascular disease (yes vs no)    | 1.24*                 | 1.05         | 1.46    |
| Baseline smoking status                             |                       |              |         |
| Smoker (vs nonsmoker)                               | 1.15                  | 0.94         | 1.40    |
| Unknown (vs nonsmoker)                              | 1.57*                 | 1.37         | 1.80    |
| Baseline CCI                                        |                       |              |         |
| CCI 1 to 3 (vs CCI=0)                               | 1.34*                 | 1.19         | 1.51    |
| CCI $\geq 4$ (vs CCI=0)                             | 1.27*                 | 1.11         | 1.45    |
| **Time-varying factors**                            |                       |              |         |
| Time-varying age group, y                           |                       |              |         |
| Age 65 to 74 vs age $<65$                           | 1.32*                 | 1.09         | 1.59    |
| Age 75 to 84 vs age $<65$                           | 2.15*                 | 1.81         | 2.56    |
| Age $\geq 85$ vs age $<65$                          | 3.15*                 | 2.63         | 3.78    |
| Time-varying congestive heart failure (yes vs no)   | 1.07                  | 0.94         | 1.22    |
| Time-varying diabetes (yes vs no)                   | 1.15*                 | 1.03         | 1.29    |
| Time-varying hypertension (yes vs no)               | 1.25*                 | 1.08         | 1.44    |
| Time-varying stroke/transient ischemic attack (yes vs no) | 3.78* | 3.16 | 4.53 | <0.0001 |
| Recent bleeding (for stroke/SE events only)        | 0.72*                 | 0.58         | 0.89    |

Results from a single multivariable regression model. CCI indicates Charlson Comorbidity Index; SE, systemic embolism; TTR, time in therapeutic range.

*Statistically significant.

DOI: 10.1161/JAHA.115.001921
to never on therapy episodes, respectively (Table 4 and Figure 2). The stroke/SE risks from off-aspirin episodes were not statistically different from never on therapy episodes; however, a 22% higher risk of stroke/SE was found from off-warfarin episodes compared to never on therapy episodes (RR = 1.22 [1.01 to 1.48]). Other significant factors associated with stroke/SE included older age, female gender, black or Hispanic race, having diabetes, hypertension, previous stroke/transient ischemic attack, peripheral vascular events, higher comorbidity score, and no experiences of recent major bleed.

Controlling for other factors, warfarin TTR <55% was associated with nearly twice the risk of a major bleed compared to never being on therapy (adjusted RR = 1.93 [1.74 to 2.14]) (Table 5, Figure 3). However, warfarin TTR ≥55% episodes were associated with a reduced risk of major bleed compared to never on therapy episodes (RR = 0.84 [0.76 to 0.93]). Similar risk was observed from the on-aspirin or off-aspirin episodes. Increased risk of bleed was observed in the off-warfarin compared to never on therapy episodes (RR = 1.54 [1.33 to 1.79]). Many factors associated with a major bleed were the same as those associated with stroke/SE including older age, black or Hispanic race, and higher comorbidity score (Tables 4 and 5). Being male, having congestive heart failure, baseline bleed, and no experience of recent stroke/SE were also associated with an increased risk of major bleed.

Subgroup analyses showed that stroke/SE as well as major bleeding events were increased in higher CHADS2 risk categories (stroke/SE event rates = 1.62 per 100 PY for CHADS2 = 1, 3.15 for CHADS2 = 2, 4.85 for CHADS2 ≥3;
warfarin TTR ≥55% or warfarin TTR <55% episodes compared to never on therapy (Figure 2). The outcomes from the lowest 25th warfarin TTR quartile (warfarin TTR <43.9%) were poor. This group reported the highest stroke/SE rates (5.37 per 100 PY) with the highest major bleed rates (17.32 per 100 PY), whereas stroke/SE rates from the highest 25th warfarin TTR quartile (warfarin TTR >71.3%) were only 0.93 per 100 PY with major bleed events of 4.59 per 100 PY (Figure 4).

Discussion

It is crucial for NVAF patients to continue antithrombotic therapy as well as maintain an adequate level of TTR for warfarin users to prevent strokes. This study shows that warfarin therapy with higher TTR range was associated with a reduction in stroke/SE for NVAF patients in a US managed-care setting. This finding is consistent with previous findings from other secondary analyses of clinical trial cohorts12–16 and a retrospective observational study,17 which emphasizes the importance of achieving and maintaining an adequate level of TTR. A significantly higher proportion of stroke/SE events occurred when the INRs were subtherapeutic (INR <2) as opposed to supratherapeutic (INR >3) (45.0% versus 13.8%, respectively). The absolute stroke/SE rates in the warfarin TTR ≥55% episodes were even lower than the event rates from the highest quartiles in some clinical trials;12,13 therefore, more distinct differences between high versus low warfarin TTR were observed from our study. This may be due to treatment selection bias; physicians might prescribe warfarin for individuals with greater perceived benefits, or this could be explained by the continuous anticoagulation management efforts from pharmacist-led clinics in KPSC.
These findings were consistent across CHADS2 stratification; the stroke/SE rates remained very low even for higher-risk patients.

Our study found that bleeding rates in the higher-warfarin TTR episodes were comparable to the rates observed among aspirin therapy episodes; however, much greater bleeding rates were found in the low-warfarin TTR episodes. Some ad-hoc analyses reported similar findings, and a systematic review article also found a negative correlation between warfarin TTR and hemorrhagic events. However, it is not clear whether the higher bleeding events observed during the low-warfarin TTR episodes were associated with INRs that were supratherapeutic or subtherapeutic, as a similar proportion of bleeding events occurred when INRs were supratherapeutic and subtherapeutic (21.0% versus 24.8%, respectively). Other factors such as concomitant antiplatelet use, alcohol intake, comorbidities, or other patient behaviors may be associated with these findings. Our study showed much greater bleeding differences between high- versus low-warfarin TTR episodes compared to the results from clinical trials, which may have been due to the relatively tight control of INR in clinical trial settings.

Bleeding rates in the never on therapy episodes were higher than the warfarin TTR ≥55% episodes. This also may have been due to treatment selection bias. Older age, higher baseline bleed, and previous fall may explain part of these findings. Higher bleeding rates were observed after warfarin discontinuation. While this finding may seem counterintuitive, 92% of these patients in the study were defined as a warfarin discontinuation due to being discharged from the anticoagulation clinic. The potential reasons for discharge from the anticoagulation clinic are often associated with the high risk of bleeds, adverse side effects, patient refusal, and nonadherence. Future studies should consider investigating reasons for high bleeding rates in these groups to better understand the population.

This study revealed that 52.4% of NVAF patients with CHADS2 ≥1 did not receive any antithrombotic therapy or were only on aspirin therapy. Interestingly, these percentages were consistent with higher CHADS2 groups (52.6% for CHADS2 ≥2, 55.3% for CHADS2 ≥3), which has also been suggested by other observational studies. However, an increasing trend of warfarin use was observed over the study period; 28.2% of the incident NVAF patients initiated warfarin during 2006–2008 and 36.0% in 2009–2011. This trend may be associated with the introduction of new guidelines calling for use of the CHADS2 score to determine warfarin use.

For warfarin users, 59.3% of person-time were either warfarin TTR <55% or off warfarin, which may represent care gaps. Moreover, this study also found a median TTR of 59% in the NVAF population. This TTR range was slightly higher than the mean TTR (53.7%) in office-based community practices in the United States, and the differences may be larger given the fact that this study only included incident NVAF patients and TTR was calculated including the inception warfarin period. However, this study shows that a substantial portion of patients were not able to achieve a high TTR. Outcomes based on the TTR quartiles showed that the lowest quartile (TTR <44%) may have driven the worse outcomes observed in the low TTR episodes (ie, given that no linear relationship between TTR and outcomes was found: stroke/SE in the upper 2 TTR quartiles were similar: 4.59 per 100 PY for TTR >71.3% versus 4.99 per 100 PY for TTR 59.1% to 71.3%). While this information might be helpful for healthcare providers and policy-makers designing interventions to improve outcomes, it is important to note that this study does not provide solid evidence regarding an appropriate TTR threshold.

The primary strength of this study was the unique data source with the availability of EMR in a large cohort. Over 20,000 of the new NVAF patients’ information were analyzed with maximum 6 years of follow-up considering longitudinal treatment patterns. In addition, we were able to separate aspirin use from the no-therapy group, and found notable differences in outcomes. Also, off-warfarin episodes were rigorously defined using actual anticoagulation pharmacist intervention data as well as lab and pharmacy records.

However, this study has limitations of observational research. This study depended on the availability and accuracy of the medical and pharmacy records provided. Accuracy or completeness of KPSC EMR data in terms of warfarin treatment has not been validated. Arbitrary grace periods (eg, 80 days for warfarin treatment and 180 days for aspirin treatment) to determine antithrombotic therapy episodes also have not been validated. Death information may not have been complete, since there is a delay in receiving death information from state and federal sources and then loading it into data systems. Challenges to defining hemorrhagic strokes and intracranial hemorrhages exist when using ICD-9-CM. ICD-9-CM code of 430, 431, and 432.x are interchangeably used to define hemorrhagic strokes and intracranial hemorrhages in retrospective observational studies. There is likely to be a selection bias due to any lack of randomization. Patients with high risk of bleeding may be less likely to receive antithrombotic therapy, and treatment effect estimates are likely to be biased when these factors are unobserved and not controlled. Novel oral anticoagulation agents were not considered in this study due to a small sample size, which might influence treatment patterns. Generalizability of the study results may also be an issue since this study only evaluated patients in KPSC. Most of the warfarin patients in KPSC are managed by...
Outcomes Associated With Antithrombotic Therapy

An et al

anticoagulation clinics, which may lead to higher warfarin TTR or lower event rates compared to usual care. NVAF management and referral systems may be different outside the KPSC system.

Conclusions

To our knowledge, the association between real-world antithrombotic treatment patterns and clinical outcomes has not been widely studied. Episodes of warfarin TTR >55% were associated with a substantial reduction in stroke/SE events in patients with NVAF, while bleeding rates were similar to the rates of the aspirin use. In contrast, warfarin TTR <55% or aspirin-only therapy was associated with a moderate stroke/SE reduction, and warfarin TTR <55% episodes were also associated with a highly increased risk of future stroke. Future studies should examine modifiable factors to improve outcomes for patients with suboptimal warfarin or for those who are off antithrombotic therapy.

Acknowledgments

The authors thank Chengyi Zheng, PhD for his work in developing natural language processing algorithm and River Koblick and Valerie Guerrero for research support.

Sources of Funding

This research and article were funded by Bristol-Myers Squibb Company and Pfizer.

Disclosures

An: grant/research support from Bristol-Myers Squibb/Pfizer, Genentech. Niu, Rashid: grant from Bristol-Myers Squibb/Pfizer to the institution for salary reimbursement. Meissner, Aranda, Bruno: Bristol-Myers Squibb employees. Mendes, Dills: Pfizer employees. Lang, Jadziewski, Le: None.

References

1. Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. J Am Cardiol. 2013;112:1142–1147.
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–988.
3. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;130:2071–2104.
4. You JY, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, Hylek EM, Schulman S, Go AS, Hughes M, Spencer FA, Manning WJ, Halperin JL, Lip GY, American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141[2 suppl]:e53S–e65S.
5. Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes. 2012;5:615–621.
6. Liu J, Sylwestrak G, Barron J, Rosenberg A, White J, Whitney J, Redberg R, Malenka D. Evaluation of practice patterns in the treatment of atrial fibrillation among the commercially insured. Curr Med Res Opin. 2014;30:1707–1713.
7. Raji MA, Lowery M, Lin YL, Kuo YF, Baillargeon J, Goodwin JS. National utilization patterns of warfarin use in older patients with atrial fibrillation: a population-based study of Medicare Part D beneficiaries. Ann Pharmacother. 2013;47:35–42.
8. Hsu J, Maddow, Kennedy, Katz D, Marzec L, Gehr A, Turakhia M, Marcus G. Predictors of aspirin versus oral anticoagulant prescription in atrial fibrillation patients at-risk for stroke: insights from the NCDR® PINNACLE Registry [Abstract]. J Am Coll Cardiol. 2014;63[12_S]:S1217–107. doi: 10.1016/S0735-1097(14)60420-4.
9. Fang MC, Go AS, Chang Y, Borovoy LH, Pommennicki NK, Udaltsova N, Singer DE. Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2010;3:624–631.
10. Gomes T, Mamdani MM, Holbrook AM, Paterson JM, Juurlink DN. Persistence with therapy among patients treated with warfarin for atrial fibrillation. Arch Intern Med. 2012;172:1687–1689.
11. Baker WL, Cios DA, Sander SD, Coleman GI. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm. 2009;15:244–252.
12. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flaher, M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ; RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376:975–983.
13. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, Healey JS, Yusuf S, ACTIVE W Investigators. Benefit of oral anticoagulant over antithrombotic therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008;118:2029–2037.
14. White HD, Gruber M, Feyzi J, Kaatz S, Tae HF, Husted S, Albers GW. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V, Arch Intern Med. 2007;167:239–245.
15. Piccini JP, Hellkamp AS, Lokhnygina Y, Patel MR, Harrell FE, Singer DE, Becker RC, Breithardt G, Halperin JL, Hankey GJ, Berkowitz SD, Nessel CC, Mahaffey KW, Fox KA, Califf RM, ROCKET AF investigators. Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. J Am Heart Assoc. 2014;3:e000521 doi: 10.1161/JAHA.113.000521.
16. Gallego P, Vilchez JA, Lane DA. Apixaban compared with warfarin for stroke prevention in atrial fibrillation: implications of time in therapeutic range. Circulation. 2013;127:1263–1265.
17. Morgan CL, McEwan P, Tukiendorf A, Robinson PA, Clemens A, Plumb JM. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb Res. 2009;124:37–41.
18. Masaki N, Suzuki M, Matsumura A, Maruyama Y, Hashimoto Y. Quality of warfarin control affects the incidence of stroke in elderly patients with atrial fibrillation. Intern Med. 2010;49:1711–1716.
19. Ogilvie IM, Welner SA, Cowell W, Lip GY. Ichaemic stroke and bleeding rates in ‘real-world’ atrial fibrillation patients. Thromb Haemost. 2011;106:34–44.
20. Rose AJ, Hylek EM, Ozonoff A, Ash AS, Reisman JJ, Berlowitz DR. Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA). J Thromb Haemost. 2010;8:2182–2191.
21. Rosendahl FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69:236–239.
22. Goodman SG, Wojdyla DM, Piccini JP, White HD, Paolini JF, Nessel CC, Berkowitz SD, Mahaffey KW, Patel MR, Sherwood MW, Becker RC, Halperin JL, Hacke W, Singer DE, Hankey GJ, Breithardt G, Fox KA, Califf RM; ROCKET AF investigators. Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol. 2014;63:981–900.
23. Rose AJ, Hylek EM, Ozonoff A, Ash AS, Reisman JI, Berlowitz DR. Risk-adjusted percent time in therapeutic range as a quality indicator for outpatient oral anticoagulation: results of the Veterans Affairs Study to Improve Anticoagulation (VARIA). Circ Cardiovasc Qual Outcomes. 2011;4:22–29.

24. Nadkarni PM, Ohno-Machado L, Chapman WW. Natural language processing: an introduction. J Am Med Inform Assoc. 2011;18:544–551.

25. Webb KH. Natural language processing and electronic medical records. JAMA. 2011;306:2325–2326.

26. Jiang M, Chen Y, Liu M, Rosenbloom ST, Mani S, Denny JC, Xu H. A study of machine-learning-based approaches to extract clinical entities and their assertions from discharge summaries. J Am Med Inform Assoc. 2011;18:601–606.

27. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antithrombotic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692–694.

28. Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P, Bankhead C, Xu Y. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes. 2008;1:84–91.

29. Hirsh J, Guyatt G, Albers GW, Harrington R, Schünemann HJ; American College of Chest Physicians. Executive summary: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133:71S–109S.

30. Dlott JS, George RA, Huang X, Odeh M, Kaufman HW, Ansell J, Hylek EM. National assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation. Circulation. 2014;129:1407–1414.

31. Andrade SE, Harrold LR, Tijia J, Cutrona SL, Szczepanski JS, Dodd KS, Goldberg R, Gurwitz JH. A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data. Pharmacoepidemiol Drug Saf. 2012;21:100–128.

32. Lichtman JH, Jones SB, Leifheit-Limson EC, Wang Y, Goldstein LB. 30-day mortality and readmission after hemorrhagic stroke among Medicare beneficiaries in Joint Commission primary stroke center-certified and noncertified hospitals. Stroke. 2011;42:3387–3391.

33. Lichtman JH, Leifheit-Limson EC, Jones SB, Wang Y, Goldstein LB. 30-Day risk-standardized mortality and readmission rates after ischemic stroke in critical access hospitals. Stroke. 2012;43:2741–2747.